TY - JOUR T1 - İnflamatuvar Barsak Hastalıklarında Osteoporoz Sıklığı TT - Osteoporosis in Inflammatory Bowel Diseases AU - Dilekçi, Erdal AU - Tezel, Ahmet AU - Can, Güray AU - Demirkol, Muhammed Emin AU - Ademoğlu Dilekçi, Esra Nur AU - Gürler, Müjgan AU - Erkuş, Edip AU - Ünsal, Gülbin AU - Soylu, Ali Rıza AU - Ümit, Hasan Celalettin AU - Akdoğan Kayhan, Meral AU - Kayhan, Mehmet AU - Keskin, Çağlar PY - 2019 DA - October DO - 10.20515/otd.441291 JF - Osmangazi Tıp Dergisi PB - Eskişehir Osmangazi Üniversitesi WT - DergiPark SN - 1305-4953 SP - 380 EP - 387 VL - 41 IS - 4 LA - tr AB - İnflamatuvar barsak hastalıkları,ağırlıklı olarak gastrointestinal sistemi tutan sistemik kronik inflamatuvarbir hastalık grubudur. İnflamatuvar barsak hastalıklarında ekstraintestinalbulgular sıklıkla birlikte bulunmaktadır. Bunlar içinde metabolik kemikhastalıkları azımsanmayacak ölçüde sıktır. Çalışmamızda kendi inflamatuvarbarsak hastalıkları kohortumuzda osteoporoz ve osteopeni sıklığını ortayakoymayı amaçladık. Buçalışmaya 71 ülseratif kolit, 44 Crohn hastasının kemik mineral dansiteverileri retrospektif olarak değerlendirildi. İnflamatuvar barsak hastalığında tanı,tutulum paterni, hastalık davranışı, cinsiyet ve kemik mineral dansitelokalizasyonlarına göre kemik dansiteleri, T ve Z skorları karşılaştırıldı. Ülseratif kolit hastalarının%53,5’inde, Crohn hastalarının %50’sinde osteopeni saptandı. Ülseratif kolitile Crohn hastalığı arasında anlamlı fark yoktu. Ülseratif kolit hastalarının%22,5’inde, Crohn hastalarının %25’inde osteoporoz saptandı. Ülseratif kolitile Crohn hastalığı arasında anlamlı fark yoktu. Crohn hastalığında osteopenien sık femur boynu ve wards üçgeninde (%47,7 ve %47,7), ülseratif kolithastalarında osteopeni en sık wards üçgeninde (%52,1) saptandı. Ülseratif kolitve Crohn hastalığında osteoporoz en sık lomber bölgede (sırasıyla %15,5 ve%18,2) tespit edildi. Ülseratif kolit ve Crohn hastalığı arasında osteoporoz veosteopeni açısından anlamlı fark izlenmedi. Ülseratif kolit ve Crohnhastalığında alttip, davranış, cinsiyet ve kemik mineral dansite lokalizasyonaçısından karşılaştırıldığında anlamlı fark saptanmadı. İnflamatuvar barsak hastalığında osteoporozve osteopeni sıklığı artmıştır. Bulgularımızı doğrulamak için daha büyükörneklem büyüklüğüyle ve iyi dizayn edilmiş prospektif çalışmalara ihtiyaçvardır. KW - İnflamatuvar barsak hastalığı KW - metabolik kemik hastalığı KW - osteoporoz KW - osteopeni N2 - Inflammatorybowel disease is a group of systemic chronic inflammatory disease thatpredominantly affects the gastrointestinal tract. Extraintestinal findings arefrequently together in inflammatory bowel disease. Of these, metabolic bonediseases are considerably frequent. In our study, we aimed to reveal thefrequency of osteoporosis and osteopenia in our own inflammatory bowel disease cohort.In this study, 71 ulcerative colitis and 44 bone mineral density data ofCrohn's patients were retrospectively evaluated. Bone densities, T and Z scoreswere compared according to involvement pattern, diagnosis, disease behavior,gender and bone mineral density localizations in inflammatory bowel disease . Osteopeniaand osteoporosis were detected in 53,5% and 22,5% of ulcerative colitispatients and in 50% and 25% of Crohn's patients respectively. There was no significantdifference between ulcerative colitis and Crohn's patients. In Crohn's patients,osteopenia was most frequently detected in the femur neck by 47,7% and in thewards triangle by 47,7%, in the ulcerative colitis, osteopenia was mostfrequently detected in the wards triangle (52,1%). In the ulcerative colitisand Crohn's patients, osteoporosis was most frequently detected in lumbarregion ( respectively 15,5% and 18,2%). There was no significant differencebetween ulcerative colitis and Crohn's patients in terms of osteopenia and osteoporosis.There was no significant difference in ulcerative colitis and Crohn's patients whencompared in terms of subtype, behavior, gender and localization of bone mineraldensity. The frequencies of osteoporosis and osteopenia increase in inflammatorybowel disease. Larger sample sizes and well-designed prospective studies areneeded to confirm our findings. CR - 1. Ott C, Schölmerich J. Extraintestinal manifestations ve complications in IBD. Nat Rev Gastroenterol Hepatol. 2013; 10: 585-95 CR - 2. Miheller P, Gesztes W, Lakatos PL. Manipulating bone disease in inflammatory bowel disease patients. Ann Gastroenterol. 2013; 26: 296-303 CR - 3. Rothfuss KS, Stange EF, Herlinger KR. Extraintestinal manifestations and complications in inflammatory bowel disease. World J Gastroenterol. 2006; 12: 4819-31 CR - 4. Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009; 122: 599-604 CR - 5. No authors listed. Assesment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tecn Rep Ser. 1994; 843: 1-129 CR - 6. Van Assche G, Dignass A, Bokemeyer, Danese S, Gionchetti P, Moser G, et al. European Crohn's and Colitis Organisation. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 3: Special situations. J Crohns colitis. 2013; 7: 1-33 CR - 7. Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol. 2005; 43: 973-83 CR - 8. Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippitt JM, et al. Colonic dendritic cells, intestinal inflammation and T cell-mediated bone destruction are modulated by recombinant osteoprotogerin. Immunity. 2003; 19: 849-61 CR - 9. Braun T, Schett G. Pathways for bone loss in inflammatory bowel disease. Curr Osteoporos Rep. 2012; 10: 101-8 CR - 10. Compston J. Osteoporosis in inflammatory bowel disease. Gut. 2003; 52(1): 63-4 CR - 11. Targownik LE, Bernstein CN, Leslie WD. Inflammatory bowel disease and the risk of osteoporosis and fracture. Maturitas. 2013; 76: 315-9 CR - 12. Miheller P, Lorinczy K, Lakatos PL. Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol. 2010; 16: 5536-42 CR - 13. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000; 133: 795-9 CR - 14. Leftus EV, Sandborn VJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin N Am. 2012; 31(1): 1-20 CR - 15. Schoon EJ, Van Nunen AB, Wounter RS, Stockbrügger RW, Russel MG, et al. Osteopenia osteoporosis in in Crohn's disease: Prevalance in a Dutch population-based cohort. Scand J Gastroenterol. 2000; 232: 43-7 CR - 16. Frei P, Fried M, Hugenbühler V. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion. 2006; 73: 40-6 CR - 17. Von Tirpitz C, Reinshagen M. Management of osteoporosis in patients with gastrointestinal disease. Eu J Gastroenterol Hepatol. 2003; 15: 869-76 CR - 18. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut. 1997; 40(1): 313-9 CR - 19. Özdemir ZT, Acar A, Karabulut L. İnflamatuar barsak hastalığında osteoporoz ve vertebra kırıkları. Bozok Tıp Derg. 2014; 4(1): 48-54 CR - 20. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003; 124: 795-841 CR - 21. Van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory disease. Scand J Gastroenterol Suppl. 2006; 243: 59-64 CR - 22. Tezel A, Can G. İnflamatuvar barsak hastalıkları ve osteoporoz. Güncel Gastroenteroloji. 2013; 17(4): 363-9 CR - 23. Targownik LE, Bernstein CN, Nugent Z, Leslie WD. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol. 2013; 11(3): 278-85 UR - https://doi.org/10.20515/otd.441291 L1 - https://dergipark.org.tr/tr/download/article-file/553711 ER -